LUX Lung 6: A randomized open label, Phase III study of Afatinib versus Gemcitabine/Cisplatin as first line treatment for Asian patients with EGFR mutation positive advanced adenocarcinoma of the lung - Wu, Y L; Zhou, C; Hu, C P (Lancet Oncol, 2014)
et al.